WallStreetZenWallStreetZen

NASDAQ: AVTX
Avalo Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AVTX

Based on 2 analysts offering 12 month price targets for Avalo Therapeutics Inc

Min Forecast
$24.00+213.32%
Avg Forecast
$32.00+317.75%
Max Forecast
$40.00+422.19%

Should I buy or sell AVTX stock?

Based on 2 analysts offering ratings for Avalo Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVTX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVTX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their AVTX stock forecasts and price targets.

AVTX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-12-19
lockedlocked$00.00+00.00%2024-12-17

1 of 1

Forecast return on equity

Is AVTX forecast to generate an efficient return?

Company
-87.78%
Industry
239.02%
Market
89.49%
AVTX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AVTX forecast to generate an efficient return on assets?

Company
-18.79%
Industry
35.08%
AVTX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVTX earnings per share forecast

What is AVTX's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$4.70
Avg 2 year Forecast
-$3.00
Avg 3 year Forecast
-$1.64

AVTX revenue growth forecast

How is AVTX forecast to perform vs Biotechnology companies and vs the US market?

Company
6.84%
Industry
49.9%
Market
11.74%
AVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AVTX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AVTX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVTX$7.66$32.00+317.75%Strong Buy
ABOS$1.33$10.50+689.47%Strong Buy
XFOR$0.47$2.75+486.35%Strong Buy
IMAB$0.97$8.00+724.74%Buy
CUE$1.27$4.00+214.96%Strong Buy
View Top Biotech Stocks

Avalo Therapeutics Stock Forecast FAQ

Is Avalo Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: AVTX) stock is to Strong Buy AVTX stock.

Out of 2 analysts, 2 (100%) are recommending AVTX as a Strong Buy, 0 (0%) are recommending AVTX as a Buy, 0 (0%) are recommending AVTX as a Hold, 0 (0%) are recommending AVTX as a Sell, and 0 (0%) are recommending AVTX as a Strong Sell.

If you're new to stock investing, here's how to buy Avalo Therapeutics stock.

What is AVTX's earnings growth forecast for 2025-2027?

(NASDAQ: AVTX) Avalo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.55%.

Avalo Therapeutics's earnings in 2025 is -$7,958,000.On average, 2 Wall Street analysts forecast AVTX's earnings for 2025 to be -$48,851,584, with the lowest AVTX earnings forecast at -$50,722,496, and the highest AVTX earnings forecast at -$46,980,672. On average, 2 Wall Street analysts forecast AVTX's earnings for 2026 to be -$31,181,862, with the lowest AVTX earnings forecast at -$46,564,914, and the highest AVTX earnings forecast at -$15,798,810.

In 2027, AVTX is forecast to generate -$17,046,085 in earnings, with the lowest earnings forecast at -$17,046,085 and the highest earnings forecast at -$17,046,085.

What is AVTX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: AVTX) forecast ROE is -87.78%, which is considered weak.

What is AVTX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year AVTX price target, the average AVTX price target is $32.00, with the highest AVTX stock price forecast at $40.00 and the lowest AVTX stock price forecast at $24.00.

On average, Wall Street analysts predict that Avalo Therapeutics's share price could reach $32.00 by Dec 19, 2025. The average Avalo Therapeutics stock price prediction forecasts a potential upside of 317.75% from the current AVTX share price of $7.66.

What is AVTX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: AVTX) Avalo Therapeutics's current Earnings Per Share (EPS) is -$19.41. On average, analysts forecast that AVTX's EPS will be -$4.70 for 2025, with the lowest EPS forecast at -$4.88, and the highest EPS forecast at -$4.52. On average, analysts forecast that AVTX's EPS will be -$3.00 for 2026, with the lowest EPS forecast at -$4.48, and the highest EPS forecast at -$1.52. In 2027, AVTX's EPS is forecast to hit -$1.64 (min: -$1.64, max: -$1.64).

What is AVTX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: AVTX) forecast ROA is -18.79%, which is lower than the forecast US Biotechnology industry average of 35.08%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.